var data={"title":"Treatment protocols for breast cancer","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Treatment protocols for breast cancer</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/treatment-protocols-for-breast-cancer/contributors\" class=\"contributor contributor_credentials\">Tim Brenner, PharmD, BCOP</a></dd><dd><a href=\"https://www.uptodate.com/contents/treatment-protocols-for-breast-cancer/contributors\" class=\"contributor contributor_credentials\">Shrina Duggal, PharmD, BCOP</a></dd><dd><a href=\"https://www.uptodate.com/contents/treatment-protocols-for-breast-cancer/contributors\" class=\"contributor contributor_credentials\">Jim Natale, PharmD, BCOP</a></dd><dd><a href=\"https://www.uptodate.com/contents/treatment-protocols-for-breast-cancer/contributors\" class=\"contributor contributor_credentials\">Scott M Wirth, PharmD, BCOP</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/treatment-protocols-for-breast-cancer/contributors\" class=\"contributor contributor_credentials\">John W Mucenski, PharmD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/treatment-protocols-for-breast-cancer/contributors\" class=\"contributor contributor_credentials\">Sadhna R Vora, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/treatment-protocols-for-breast-cancer/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Jan 27, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H12702398\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The following material represents a subset of chemotherapy regimens that are used for the treatment of patients with breast cancer, both in the adjuvant and neoadjuvant settings. <strong>This is</strong> <strong>not an exhaustive list</strong>; it includes regimens that are considered by the authors and editors to be commonly used and important for the care of patients with breast cancer. Additional regimens may be added over time, particularly as treatment for breast cancer evolves.</p><p>This topic review is intended to provide only a listing of chemotherapy regimens. It does not address the appropriate context for use of these regimens in the care of patients with breast cancer. Clinicians should refer to the individual disease-oriented topic reviews that discuss the use of these protocols in appropriate clinical situations:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=adjuvant-chemotherapy-for-her2-negative-breast-cancer\" class=\"medical medical_review\">&quot;Adjuvant chemotherapy for HER2-negative breast cancer&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=adjuvant-systemic-therapy-for-her2-positive-breast-cancer\" class=\"medical medical_review\">&quot;Adjuvant systemic therapy for HER2-positive breast cancer&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=general-principles-of-neoadjuvant-therapy-for-breast-cancer\" class=\"medical medical_review\">&quot;General principles of neoadjuvant therapy for breast cancer&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=systemic-treatment-of-metastatic-breast-cancer-in-women-chemotherapy\" class=\"medical medical_review\">&quot;Systemic treatment of metastatic breast cancer in women: Chemotherapy&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=systemic-treatment-for-her2-positive-metastatic-breast-cancer\" class=\"medical medical_review\">&quot;Systemic treatment for HER2-positive metastatic breast cancer&quot;</a>.)</p><p/><p>These tables are provided as examples of how to administer these regimens; there may be other acceptable methods. All chemotherapy regimens must be administered by clinicians who are trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</p><p class=\"headingAnchor\" id=\"H12702620\"><span class=\"h1\">REGIMENS</span></p><p class=\"headingAnchor\" id=\"H12702628\"><span class=\"h2\">Regimens for HER2-negative breast cancer</span></p><p class=\"headingAnchor\" id=\"H931995884\"><span class=\"h3\">TC (docetaxel plus cyclophosphamide)</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F56545\" class=\"graphic graphic_table graphicRef56545 \">table 1</a>)</p><p class=\"headingAnchor\" id=\"H931995909\"><span class=\"h3\">Dose-dense ACT (doxorubicin plus cyclophosphamide followed by paclitaxel)</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F55933\" class=\"graphic graphic_table graphicRef55933 \">table 2</a>)</p><p class=\"headingAnchor\" id=\"H931995934\"><span class=\"h3\">AC (doxorubicin plus cyclophosphamide)</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F78493\" class=\"graphic graphic_table graphicRef78493 \">table 3</a>)</p><p class=\"headingAnchor\" id=\"H931995959\"><span class=\"h3\">ACT (doxorubicin plus cyclophosphamide followed by weekly paclitaxel)</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F69273\" class=\"graphic graphic_table graphicRef69273 \">table 4</a>)</p><p class=\"headingAnchor\" id=\"H527737597\"><span class=\"h3\">TAC (docetaxel, doxorubicin, and cyclophosphamide)</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F89386\" class=\"graphic graphic_table graphicRef89386 \">table 5</a>)</p><p class=\"headingAnchor\" id=\"H931996017\"><span class=\"h3\">Oral CMF (oral cyclophosphamide plus methotrexate and fluorouracil)</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F69601\" class=\"graphic graphic_table graphicRef69601 \">table 6</a>)</p><p class=\"headingAnchor\" id=\"H29982684\"><span class=\"h3\">IV CMF (IV cyclophosphamide plus methotrexate and fluorouracil)</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F86827\" class=\"graphic graphic_table graphicRef86827 \">table 7</a>)</p><p class=\"headingAnchor\" id=\"H29982798\"><span class=\"h3\">FEC (fluorouracil, epirubicin, plus cyclophosphamide)</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F86828\" class=\"graphic graphic_table graphicRef86828 \">table 8</a>)</p><p class=\"headingAnchor\" id=\"H29982691\"><span class=\"h3\">FEC followed by weekly paclitaxel</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F86825\" class=\"graphic graphic_table graphicRef86825 \">table 9</a>)</p><p class=\"headingAnchor\" id=\"H1232629016\"><span class=\"h3\">FEC followed by weekly docetaxel</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F86826\" class=\"graphic graphic_table graphicRef86826 \">table 10</a>)</p><p class=\"headingAnchor\" id=\"H12702676\"><span class=\"h2\">Regimens for HER2-positive breast cancer</span></p><p class=\"headingAnchor\" id=\"H6081146\"><span class=\"h3\">Neoadjuvant pertuzumab, trastuzumab, and docetaxel followed by adjuvant FEC plus trastuzumab</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F96371\" class=\"graphic graphic_table graphicRef96371 \">table 11</a>)</p><p class=\"headingAnchor\" id=\"H6081160\"><span class=\"h3\">Neoadjuvant trastuzumab, pertuzumab, carboplatin, and docetaxel</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F96372\" class=\"graphic graphic_table graphicRef96372 \">table 12</a>)</p><p class=\"headingAnchor\" id=\"H6081167\"><span class=\"h3\">Neoadjuvant FEC followed by docetaxel, pertuzumab, and trastuzumab</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F96464\" class=\"graphic graphic_table graphicRef96464 \">table 13</a>)</p><p class=\"headingAnchor\" id=\"H2358344396\"><span class=\"h3\">ACTH (doxorubicin plus cyclophosphamide followed by paclitaxel plus trastuzumab)</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F54687\" class=\"graphic graphic_table graphicRef54687 \">table 14</a>)</p><p class=\"headingAnchor\" id=\"H2358344435\"><span class=\"h3\">Pertuzumab, trastuzumab, and docetaxel</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F96342\" class=\"graphic graphic_table graphicRef96342 \">table 15</a>)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"topicVersionRevision\">Topic 85677 Version 16.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li><a href=\"#H12702398\" id=\"outline-link-H12702398\">INTRODUCTION</a></li><li><a href=\"#H12702620\" id=\"outline-link-H12702620\">REGIMENS</a><ul><li><a href=\"#H12702628\" id=\"outline-link-H12702628\">Regimens for HER2-negative breast cancer</a><ul><li><a href=\"#H931995884\" id=\"outline-link-H931995884\">- TC (docetaxel plus cyclophosphamide)</a></li><li><a href=\"#H931995909\" id=\"outline-link-H931995909\">- Dose-dense ACT (doxorubicin plus cyclophosphamide followed by paclitaxel)</a></li><li><a href=\"#H931995934\" id=\"outline-link-H931995934\">- AC (doxorubicin plus cyclophosphamide)</a></li><li><a href=\"#H931995959\" id=\"outline-link-H931995959\">- ACT (doxorubicin plus cyclophosphamide followed by weekly paclitaxel)</a></li><li><a href=\"#H527737597\" id=\"outline-link-H527737597\">- TAC (docetaxel, doxorubicin, and cyclophosphamide)</a></li><li><a href=\"#H931996017\" id=\"outline-link-H931996017\">- Oral CMF (oral cyclophosphamide plus methotrexate and fluorouracil)</a></li><li><a href=\"#H29982684\" id=\"outline-link-H29982684\">- IV CMF (IV cyclophosphamide plus methotrexate and fluorouracil)</a></li><li><a href=\"#H29982798\" id=\"outline-link-H29982798\">- FEC (fluorouracil, epirubicin, plus cyclophosphamide)</a></li><li><a href=\"#H29982691\" id=\"outline-link-H29982691\">- FEC followed by weekly paclitaxel</a></li><li><a href=\"#H1232629016\" id=\"outline-link-H1232629016\">- FEC followed by weekly docetaxel</a></li></ul></li><li><a href=\"#H12702676\" id=\"outline-link-H12702676\">Regimens for HER2-positive breast cancer</a><ul><li><a href=\"#H6081146\" id=\"outline-link-H6081146\">- Neoadjuvant pertuzumab, trastuzumab, and docetaxel followed by adjuvant FEC plus trastuzumab</a></li><li><a href=\"#H6081160\" id=\"outline-link-H6081160\">- Neoadjuvant trastuzumab, pertuzumab, carboplatin, and docetaxel</a></li><li><a href=\"#H6081167\" id=\"outline-link-H6081167\">- Neoadjuvant FEC followed by docetaxel, pertuzumab, and trastuzumab</a></li><li><a href=\"#H2358344396\" id=\"outline-link-H2358344396\">- ACTH (doxorubicin plus cyclophosphamide followed by paclitaxel plus trastuzumab)</a></li><li><a href=\"#H2358344435\" id=\"outline-link-H2358344435\">- Pertuzumab, trastuzumab, and docetaxel</a></li></ul></li></ul></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"ONC/85677|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=ONC/56545\" class=\"graphic graphic_table\">- TC regimen for breast cancer</a></li><li><a href=\"image.htm?imageKey=ONC/55933\" class=\"graphic graphic_table\">- Dose dense AC-T breast cancer</a></li><li><a href=\"image.htm?imageKey=ONC/78493\" class=\"graphic graphic_table\">- AC regimen for breast cancer</a></li><li><a href=\"image.htm?imageKey=ONC/69273\" class=\"graphic graphic_table\">- AC-T for breast cancer</a></li><li><a href=\"image.htm?imageKey=ONC/89386\" class=\"graphic graphic_table\">- TAC</a></li><li><a href=\"image.htm?imageKey=ONC/69601\" class=\"graphic graphic_table\">- Oral CMF for breast cancer</a></li><li><a href=\"image.htm?imageKey=ONC/86827\" class=\"graphic graphic_table\">- IV CMF for breast cancer</a></li><li><a href=\"image.htm?imageKey=ONC/86828\" class=\"graphic graphic_table\">- FEC for MBC</a></li><li><a href=\"image.htm?imageKey=ONC/86825\" class=\"graphic graphic_table\">- FEC plus paclitaxel for MBC</a></li><li><a href=\"image.htm?imageKey=ONC/86826\" class=\"graphic graphic_table\">- FEC plus docetaxel for MBC</a></li><li><a href=\"image.htm?imageKey=ONC/96371\" class=\"graphic graphic_table\">- NEOSPHERE</a></li><li><a href=\"image.htm?imageKey=ONC/96372\" class=\"graphic graphic_table\">- TRYPHAENA</a></li><li><a href=\"image.htm?imageKey=ONC/96464\" class=\"graphic graphic_table\">- TRYPHAENA - FEC then DHP</a></li><li><a href=\"image.htm?imageKey=ONC/54687\" class=\"graphic graphic_table\">- AC followed by TH regimen</a></li><li><a href=\"image.htm?imageKey=ONC/96342\" class=\"graphic graphic_table\">- Pertuzumab trastuzumab and docetaxel MBC</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=adjuvant-chemotherapy-for-her2-negative-breast-cancer\" class=\"medical medical_review\">Adjuvant chemotherapy for HER2-negative breast cancer</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=adjuvant-systemic-therapy-for-her2-positive-breast-cancer\" class=\"medical medical_review\">Adjuvant systemic therapy for HER2-positive breast cancer</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=general-principles-of-neoadjuvant-therapy-for-breast-cancer\" class=\"medical medical_review\">General principles of neoadjuvant therapy for breast cancer</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=systemic-treatment-for-her2-positive-metastatic-breast-cancer\" class=\"medical medical_review\">Systemic treatment for HER2-positive metastatic breast cancer</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=systemic-treatment-of-metastatic-breast-cancer-in-women-chemotherapy\" class=\"medical medical_review\">Systemic treatment of metastatic breast cancer in women: Chemotherapy</a></li></ul></div></div>","javascript":null}